Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1884 1
1886 1
1890 1
1892 1
1896 2
1978 1
1981 1
1992 1
1993 2
1995 2
1996 1
1997 3
1998 5
1999 4
2000 7
2001 1
2002 3
2003 5
2005 4
2006 8
2007 10
2008 8
2009 3
2010 6
2011 5
2012 5
2013 5
2014 4
2015 5
2016 6
2017 5
2018 7
2019 5
2020 11
2021 12
2022 11
2023 8
2024 4
2025 6
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chiò A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Nestorov I, Graham D, Sun P, McNeill M, Fanning L, Ferguson TA, Fradette S; VALOR and OLE Working Group. Miller TM, et al. Among authors: andrews ja. N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705. N Engl J Med. 2022. PMID: 36129998 Free article. Clinical Trial.
Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.
Miller TM, Cudkowicz ME, Shaw PJ, Genge A, Sobue G, Bucelli RC, Chiò A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Salachas F, Bruneteau G, Al-Chalabi A, Amorin M, Nestorov I, Graham D, Lin L, Sun P, McNeill M, Malek S, Inra J, Garafalo S, Fradette S; VALOR and OLE Working Group. Miller TM, et al. Among authors: andrews ja. JAMA Neurol. 2026 Feb 1;83(2):115-125. doi: 10.1001/jamaneurol.2025.4946. JAMA Neurol. 2026. PMID: 41661214 Free PMC article. Clinical Trial.
Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series.
Shneider NA, Harms MB, Korobeynikov VA, Rifai OM, Hoover BN, Harrington EA, Aziz-Zaman S, Singleton J, Jamil A, Madan VR, Lee I, Andrews JA, Smiley RM, Alam MM, Black LE, Shin M, Watts JK, Walk D, Newman D, Pascuzzi RM, Weber M, Neuwirth C, Da Cruz S, Soriano A, Lane R, Henry S, Mathews J, Jafar-Nejad P, Norris D, Rigo F, Brown RH, Miller S, Crean R, Bennett CF. Shneider NA, et al. Among authors: andrews ja. Lancet. 2025 Jun 7;405(10494):2075-2086. doi: 10.1016/S0140-6736(25)00513-6. Epub 2025 May 22. Lancet. 2025. PMID: 40414239 Free PMC article.
Association Between Initial Use of e-Cigarettes and Subsequent Cigarette Smoking Among Adolescents and Young Adults: A Systematic Review and Meta-analysis.
Soneji S, Barrington-Trimis JL, Wills TA, Leventhal AM, Unger JB, Gibson LA, Yang J, Primack BA, Andrews JA, Miech RA, Spindle TR, Dick DM, Eissenberg T, Hornik RC, Dang R, Sargent JD. Soneji S, et al. Among authors: andrews ja. JAMA Pediatr. 2017 Aug 1;171(8):788-797. doi: 10.1001/jamapediatrics.2017.1488. JAMA Pediatr. 2017. PMID: 28654986 Free PMC article.
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M, Farahany NA, Harrington EA, Chen W, Mitchell AA, Ferguson T, Chew S, Gedney L, Oakley S, Heo J, Chary S, Fanning L, Graham D, Sun P, Liu Y, Wong J, Fradette S. Benatar M, et al. Among authors: andrews ja. Neurotherapeutics. 2022 Jul;19(4):1248-1258. doi: 10.1007/s13311-022-01237-4. Epub 2022 May 18. Neurotherapeutics. 2022. PMID: 35585374 Free PMC article.
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial.
Shefner JM, Cudkowicz ME, Genge A, Hardiman O, Al-Chalabi A, Andrews JA, Chio A, Corcia P, Couratier P, de Carvalho M, Heiman-Patterson T, Henderson RD, Ingre C, Johnston W, Ludolph A, Maragakis NJ, Miller TM, Mora JS, Petri S, Simmons Z, van den Berg LH, Zinman L, Kupfer S, Malik FI, Meng L, Simkins TJ, Wei J, Wolff AA, Rudnicki SA; COURAGE-ALS Study Group. Shefner JM, et al. Among authors: andrews ja. JAMA Neurol. 2025 May 1;82(5):477-485. doi: 10.1001/jamaneurol.2025.0241. JAMA Neurol. 2025. PMID: 40126464 Free PMC article. Clinical Trial.
Jequirity Ophthalmia.
Andrews JA. Andrews JA. Trans Am Ophthalmol Soc. 1884;3:679-85. Trans Am Ophthalmol Soc. 1884. PMID: 16691772 Free PMC article. No abstract available.
Hospitalizations as an outcome measure in COURAGE-ALS.
Rudnicki SA, Al-Chalabi A, Andrews JA, Chio A, Corcia P, Couratier P, Cudkowicz ME, De Carvalho M, Genge A, Hardiman O, Heiman-Patterson T, Henderson RD, Ingre C, Johnston W, Ludolph A, Maragakis NJ, Miller TM, Mora JS, Petri S, Simmons Z, Van Den Berg LH, Zinman L, Herder KE, Kupfer S, Malik FI, Meng L, Simkins TJ, Wei J, Wolff AA, Shefner JM; Courage-Als study group. Rudnicki SA, et al. Among authors: andrews ja. Amyotroph Lateral Scler Frontotemporal Degener. 2025 Nov;26(7-8):802-811. doi: 10.1080/21678421.2025.2515907. Epub 2025 Jun 12. Amyotroph Lateral Scler Frontotemporal Degener. 2025. PMID: 40503807 Free article. Clinical Trial.
167 results